Instrument Inactif

Communiqués Quest PharmaTech Inc. Other OTC

Actions

QPTFF

CA74836M1068

Recherche biotechnologique et médicale

Communiqués

29/05	Quest PharmaTech Provides Corporate Update including Voluntary Adoption of CSA Blanket Order 51-93 to File Financial Statements and MD&A on Semi-Annual Basis	AQ
27/08/25	Quest PharmaTech Announces Results from AGM	AQ
11/06/25	Quest PharmaTech Announces Opposition to OQPBIOM's Acquisition of AdBioTech	AQ
02/06/25	Quest PharmaTech Provides Corporate Update	AQ
11/10/24	Quest PharmaTech Announces Results from AGM	AQ
30/05/24	Quest PharmaTech Announces Filing of 2024 Year End Financial Statements and Restated Fiscal 2023 Financial Statements, and Appointment of New Director	AQ
30/01/24	Quest Receives Cash Dividend Payment from OncoQuest	AQ
24/01/24	Quest PharmaTech Inc. - Oregovomab Phase III Clinical Study fails futility analysis, Data Safety Monitoring Board Recommends Overall Survival Follow Up for Potential Late Immune Effects and Clinical Benefits	AQ
23/01/24	Oregovomab Phase III Clinical Study fails futility analysis; Data Safety Monitoring Board Recommends Overall Survival Follow Up for Potential Late Immune Effects and Clinical Benefits	AQ
13/09/23	Quest PharmaTech Provides Corporate Update	AQ
14/07/23	Quest PharmaTech Announces Results from AGM	AQ
10/07/23	Quest PharmaTech Provides Product Development Update	AQ
09/06/23	Quest PharmaTech Provides Corporate Update	AQ
07/06/23	Canadian Investment Regulatory Organization Trade Resumption - QPT	AQ
06/06/23	Quest PharmaTech Clarifies Agreement in Principle with OQP Bio Inc.	AQ
06/06/23	Canadian Investment Regulatory Organization Trading Halt - QPT	AQ
02/06/23	Quest PharmaTech Provides Corporate Update	AQ
28/09/22	Quest PharmaTech Announces Sale of Bioceltran Investment and Return of Photodynamic Therapy Technology License	AQ
21/07/22	Quest PharmaTech Announces Results from AGM	AQ
19/04/22	Quest PharmaTech Provides Corporate Update	AQ
02/09/21	Quest PharmaTech : September 1, 2021 OncoQuest Pharmaceuticals Inc. Announces First Patient Enrolled in Each of Two Investigator Initiated Clinical Trials of Oregovomab in Combination Therapy for the Treatment of Recurrent Ovarian Cancer	PU
01/09/21	Quest PharmaTech : OncoQuest Pharmaceuticals Inc. Announces First Patient Enrolled in Each of Two Investigator Initiated Clinical Trials of Oregovomab in Combination Therapy for the Treatment of Recurrent Ovarian Cancer	AQ
08/07/21	Quest PharmaTech : July 7, 2021 Quest PharmaTech Announces Results from AGM	PU
07/07/21	Quest PharmaTech : Announces Results from AGM	AQ
02/06/21	Quest PharmaTech : June 1, 2021 Quest PharmaTech Announces two presentations by OncoQuest Pharmaceuticals, Inc. at the 2021 Annual Meeting of the American Association of Clinical Oncologists	PU